Agios Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AGIO
CUSIP
00847X104
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00847X104 since 12/18/2024, largest first.

Filer % of Class Filed
Farallon Capital Management, L.L.C. 13G/A
9.9% 8/3/2026
Event 6/30/2026
Farallon Capital Partners, L.P. 13G/A
8.8% 2/9/2026
Event 12/31/2025
BlackRock, Inc. 13G/A 7.8% 7/17/2025
Event 6/30/2025
State Street Corp 13G 5.3% 2/9/2026
Event 12/31/2025
Vanguard Capital Management LLC 13G 5.3% 4/29/2026
Event 3/31/2026
D. E. Shaw & Co., L.P. 13G
5.1% 7/2/2026
Event 6/25/2026
Lynx1 Capital Management LP 13G
5.1% 5/6/2026
Event 4/29/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Paradigm Biocapital Advisors LP 13G/A
4.9% 11/14/2025
Event 9/30/2025
Armistice Capital, LLC 13G/A
4.6% 5/15/2026
Event 3/31/2026
BB Biotech AG 13G/A
0% 6/13/2025
Event 6/1/2025
Bellevue Group AG 13G/A
0% 12/5/2025
Event 11/19/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 3.35 k $111 k
2026 Q2 254 68.6 M $2.52 B
2026 Q1 251 63.1 M $2.12 B
2025 Q4 261 61.3 M $1.67 B
2025 Q3 249 63.7 M $2.55 B
2025 Q2 228 62.3 M $2.07 B
2025 Q1 235 60.1 M $1.76 B
2024 Q4 240 59.8 M $1.97 B
2024 Q3 231 59.9 M $2.66 B
2024 Q2 226 60.8 M $2.62 B
2024 Q1 211 67.1 M $1.96 B
2023 Q4 189 63.8 M $1.42 B
2023 Q3 164 59.4 M $1.47 B
2023 Q2 168 59.4 M $1.68 B
2023 Q1 180 59.2 M $1.36 B
2022 Q4 179 62.7 M $1.76 B
2022 Q3 190 58.4 M $1.65 B
2022 Q2 172 59.2 M $1.31 B
2022 Q1 184 60.2 M $1.75 B
2021 Q4 183 59.4 M $1.95 B
2021 Q3 180 60.9 M $2.81 B
2021 Q2 205 65.9 M $3.63 B
2021 Q1 195 65.3 M $3.37 B
2020 Q4 234 65.6 M $2.84 B
2020 Q3 231 65.9 M $2.30 B
2020 Q2 240 67.9 M $3.63 B
2020 Q1 227 69.6 M $2.48 B
2019 Q4 226 70.0 M $3.34 B
2019 Q3 212 63.1 M $2.05 B
2019 Q2 214 61.3 M $3.06 B
2019 Q1 224 60.1 M $4.06 B
2018 Q4 218 58.6 M $2.70 B
2018 Q3 231 57.0 M $4.39 B
2018 Q2 238 54.9 M $4.63 B
2018 Q1 216 55.7 M $4.55 B
2017 Q4 193 47.0 M $2.69 B
2017 Q3 186 46.1 M $3.07 B
2017 Q2 183 46.2 M $2.37 B
2017 Q1 170 41.1 M $2.40 B
2016 Q4 177 39.1 M $1.63 B
2016 Q3 177 37.9 M $2.00 B
2016 Q2 167 34.1 M $1.43 B
2016 Q1 169 33.8 M $1.37 B
2015 Q4 161 33.2 M $2.15 B
2015 Q3 161 31.5 M $2.22 B
2015 Q2 170 30.1 M $3.35 B
2015 Q1 159 28.0 M $2.64 B
2014 Q4 155 27.7 M $3.10 B
2014 Q3 125 24.5 M $1.50 B
2014 Q2 105 24.9 M $1.14 B
2014 Q1 76 20.5 M $804 M